Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 448 recent clinical mold isolates. The endpoint for reading caspofungin was the minimum effective concentration (MEC). Among the triazoles, posaconazole was most active, inhibiting 95% of isolates at ≤1 μg/ml, followed by ravuconazole (91%), voriconazole (90%), and itraconazole (79%). Caspofungin and amphotericin B inhibited 93% and 89% of isolates at ≤1 μg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 μg/ml. All three new triazoles and caspofungin inhibited >95% of Aspergillus spp. at ≤1 μg/ml compared to 83% for itraconazole and 91% for amphotericin B. Amphotericin B inhibited only 38% of Aspergillus terreus isolates at ≤1 μg/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at ≤0.5 μg/ml. The new triazoles and caspofungin have excellent in vitro activity against a very large collection of recent clinical isolates of Aspergillus spp., and some in vitro activity against selected other filamentous fungi.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis
Herbrecht, R., Denning, D. W., Patterson, T. F., Bennett, J. E., Greene, R. E., Oestmann, J.-W., Kern, W. V., Marr, K. A., Ribaud, P., Lortholary, O., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020191 · Cited by 3,304
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
Espinel-Ingroff, A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2950-2956.1998 · Cited by 576
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Self-citationKurtz, M. B., Heath, I. B., Marrinan, J., Dreikorn, S., Onishi, J., & Douglas, C. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1480 · Cited by 320
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 314
Espinel-Ingroff, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.954-958.2001 · Cited by 296
Kirkpatrick, W. R., Perea, S., Coco, B. J., & Patterson, T. F. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2564-2568.2002 · Cited by 282
In Vitro Synergy of Caspofungin and Amphotericin B against Aspergillus and Fusarium spp
Arikan, S., Lozano-Chiu, M., Paetznick, V., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.245-247.2002 · Cited by 280
Denning, D. W., Marinus, A., Cohen, J., Spence, D., Herbrecht, R., Pagano, L., Kibbler, C., Kermery, V., Offner, F., Cordonnier, C., et al. (1998) · Journal of Infection · doi:10.1016/s0163-4453(98)80173-4 · Cited by 256
Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents
Barry, A. L., Pfaller, M. A., Brown, S. D., Espinel-Ingroff, A., Ghannoum, M. A., Knapp, C., Rennie, R. P., Rex, J. H., & Rinaldi, M. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.9.3457-3459.2000 · Cited by 211
Self-citationIn Vitro Susceptibility Testing Methods for Caspofungin against Aspergillus and Fusarium Isolates
Arikan, S., Lozano-Chiu, M., Paetznick, V., & Rex, J. H. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.327-330.2001 · Cited by 202
Radford, S. A., Johnson, E. M., & Warnock, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.4.841 · Cited by 189
Iwen, P. C., Rupp, M. E., Langnas, A. N., Reed, E. C., & Hinrichs, S. H. (1998) · Clinical Infectious Diseases · doi:10.1086/520297 · Cited by 172
Burden of aspergillosis-related hospitalizations in the United States
Dasbach, E. J., Davies, G. M., & Teutsch, S. M. (2000) · Clinical Infectious Diseases · doi:10.1086/317487 · Cited by 159
In vitro evaluation of voriconazole against some clinically important fungi
McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper, C. R., & Rinaldi, M. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.8.1832 · Cited by 132
Oakley, K. L., Moore, C. B., & Denning, D. W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1124 · Cited by 101
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Medical Mycology · doi:10.1080/02681219880000691 · Cited by 90
Self-citationCaspofungin in Combination with Itraconazole for the Treatment of Invasive Aspergillosis in Humans
Rubin, M. A., Carroll, K. C., & Cahill, B. C. (2002) · Clinical Infectious Diseases · doi:10.1086/339755 · Cited by 76
Caspofungin acetate: An antifungal agent
Hoang, A. (2001) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/58.13.1206 · Cited by 68
Arikan, S., Paetznick, V., & Rex, J. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3084-3087.2002 · Cited by 67
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Mycopathologia · doi:10.1023/a:1006970503053 · Cited by 54
Self-citationSafdar, A. (2002) · Clinical Infectious Diseases · doi:10.1086/340260 · Cited by 48
Koss, T., Bagheri, B., Zeana, C. B., Romagnoli, M. F., & Grossman, M. E. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120627 · Cited by 36
Marco, F., Pfaller, M. A., Messer, S. A., & Jones, R. N. (1998) · Medical Mycology · doi:10.1046/j.1365-280x.1998.00170.x · Cited by 28
Self-citation
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citationNovel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Aspergillus flavus: human pathogen, allergen and mycotoxin producer
Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., & Denning, D. W. (2007) · Microbiology · doi:10.1099/mic.0.2007/007641-0 · Cited by 964
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citationPfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Self-citation
Metadata
- Authors
- Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A.
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2003-08
- Volume
- 41
- Issue
- 8
- Pages
- 3623-3626
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W2140467714
- Cited by
- 371
- References
- 28
- FWCI
- 16.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.